Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annette M Chang

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Diabetes and Its Complications|November 30, 2023
Fasting and postprandial plasma glucose contributions to hemoglobin A1c and time in range in people with diabetes on multiple daily injection insulin therapy: Results from the PRONTO-T1D and PRONTO-T2D clinical trialsCarolina Piras de Oliveira, Mary Anne Dellva, Juliana Bue-Valleskey, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 23, 2023
Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 DiabetesRichard M Bergenstal, Bruce W Bode, Anuj Bhargava, et al.
Diabetes Technology & Therapeutics|April 1, 2015
Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical TrialsEdward J Bastyr, Shuyu Zhang, Jiani Mou, et al.
Diabetes, Obesity & Metabolism|August 4, 2016
Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trialsJulio Rosenstock, Michel Marre, Yongming Qu, et al.
The Journal of Clinical Endocrinology and Metabolism|December 1, 2005
Limitation of the homeostasis model assessment to predict insulin resistance and beta-cell dysfunction in older peopleAnnette M Chang, Marla J Smith, Cathie J Bloem, et al.
Biomarkers in Medicine|November 22, 2017
Effects of hepato-preferential basal insulin peglispro on nuclear magnetic resonance biomarkers lipoprotein insulin resistance index and GlycA in patients with diabetesMargery A Connelly, James D Otvos, Qianyi Zhang, et al.
Diabetes|June 28, 2003
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single doseAnnette M Chang, Grethe Jakobsen, Jeppe Sturis, et al.
Lancet (London, England)|September 13, 2024
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trialRichard M Bergenstal, Ruth S Weinstock, Chantal Mathieu, et al.
Lancet (London, England)|June 25, 2025
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trialThomas Blevins, Dominik Dahl, Federico C Pérez Manghi, et al.
Diabetes Care|November 19, 2015
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5John B Buse, Helena W Rodbard, Carlos Trescoli Serrano, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Diabetes and Its Complications|November 30, 2023
Fasting and postprandial plasma glucose contributions to hemoglobin A1c and time in range in people with diabetes on multiple daily injection insulin therapy: Results from the PRONTO-T1D and PRONTO-T2D clinical trialsCarolina Piras de Oliveira, Mary Anne Dellva, Juliana Bue-Valleskey, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 23, 2023
Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 DiabetesRichard M Bergenstal, Bruce W Bode, Anuj Bhargava, et al.
Diabetes Technology & Therapeutics|April 1, 2015
Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical TrialsEdward J Bastyr, Shuyu Zhang, Jiani Mou, et al.
Diabetes, Obesity & Metabolism|August 4, 2016
Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trialsJulio Rosenstock, Michel Marre, Yongming Qu, et al.
The Journal of Clinical Endocrinology and Metabolism|December 1, 2005
Limitation of the homeostasis model assessment to predict insulin resistance and beta-cell dysfunction in older peopleAnnette M Chang, Marla J Smith, Cathie J Bloem, et al.
Biomarkers in Medicine|November 22, 2017
Effects of hepato-preferential basal insulin peglispro on nuclear magnetic resonance biomarkers lipoprotein insulin resistance index and GlycA in patients with diabetesMargery A Connelly, James D Otvos, Qianyi Zhang, et al.
Diabetes|June 28, 2003
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single doseAnnette M Chang, Grethe Jakobsen, Jeppe Sturis, et al.
Lancet (London, England)|September 13, 2024
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trialRichard M Bergenstal, Ruth S Weinstock, Chantal Mathieu, et al.
Lancet (London, England)|June 25, 2025
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trialThomas Blevins, Dominik Dahl, Federico C Pérez Manghi, et al.
Diabetes Care|November 19, 2015
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5John B Buse, Helena W Rodbard, Carlos Trescoli Serrano, et al.
Pageof 3